C16 Biosciences vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised $20M Series A led by Breakthrough Energy Ventures;
About
C16 Biosciences is a biotechnology company founded in 2017 by David Heller, Irina Gerry, and Harry McNamara and headquartered in New York City. The company developed a proprietary biomanufacturing platform that uses engineered yeast fermentation to produce Palmless — a sustainable, palm oil-equivalent ingredient designed for beauty, personal care, and food applications. Palm oil is one of the most widely used commodity oils in the world, but its production is responsible for massive tropical deforestation, habitat destruction, and biodiversity loss, particularly in Indonesia and Malaysia. C16's fermentation approach produces oils with the same functional performance as palm oil — high saturation, solid at room temperature, neutral flavor — without any agricultural land conversion.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.